Cell line · CVCL_0313
Papers83
3 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 83
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer. | Cancer Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Integrin β6-Targeted Antibody-Drug Conjugate Optimized for Intravesical Delivery to Treat Non-Muscle-Invasive Bladder Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ADCE-T02: A Next-generation Antibody-Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. | Nat Cell Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of Regulator of G Protein Signaling 11 Promotes Protumorigenic Features in Pancreatic Cancer. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0313/papers